Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate-Reference-Cited by-同舟云学术

Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate

Published:2008-04 Issue:2 Volume:18 Page:104-111
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:Melanoma Research

Author:

Hofbauer Günther F.L.,Baur Tobias,Bonnet Marie-Claude,Tartour Eric,Burg Günter,Berinstein Neil L.,Dummer Reinhard

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference33 articles.

1. Immunotherapy for melanoma

2. Intralesional interferon-alpha therapy in advanced malignant melanoma

3. Regression of In-Transit Melanoma of the Scalp With Intralesional Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor

4. Intratumoral Injection of DNA Encoding Human Interleukin 12 into Patients with Metastatic Melanoma: Clinical Efficacy

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oncolytic myxoma virus is effective in murine models of triple negative breast cancer despite poor rates of infection;Molecular Therapy - Oncolytics;2023-09

2. Intratumoral therapies and in-situ vaccination for melanoma;Human Vaccines & Immunotherapeutics;2022-05-13

3. Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers;American Journal of Clinical Dermatology;2019-06-21

4. Cancer Immunotherapy;Withrow and MacEwen's Small Animal Clinical Oncology;2019

5. Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors;Cancer Immunology, Immunotherapy;2017-02-25